CARB-X supports BioVersys in the fight against antimicrobial resistance with up to almost 9 million dollars
BioVersys receives CARB-X Award of up to US$ 8.92 Million for Development of Novel Antimicrobial Therapies:
Innovation in the fight against a creeping pandemic
Cellestia presented promising clinical data of its lead comp...
Monte Rosa Therapeutics Announces $96 Million Series B Finan...
BioVersys Announces CHF 19 Million Financing to Advance Nove...
We are hiring: Marketing and Stakeholder Relations Technolog...